(1) Performance status of 2 or greater(2) Advanced liver function abnormalities classified as grade C by the Child-Pugh criteria(3) End-stage renal disease requiring dialysis(4) Altered mental status(5) Pregnant or planning pregnancy(6) If female, not agreeable to using oral contraceptive, intrauterine contraceptive device, mechanical contraceptive methods such as pessaries and condoms, or combinations thereof, during favipiravir administration and 90 days thereafter(7) If male, has a female partner who is not agreeable to the contraceptive methods described in (7) (8) If male, not agreeable to using condoms during favipiravir administration and 90 days thereafter(9) History of hereditary xanthine oxidase deficiency(10) History of hypouricemia (less than 1 mg/dL) or xanthine urolithiasis(11) History of uncontrolled gout or hyperuricemia (12) History of immunocompromising conditions such as HIV positivity(13) Has received systemic agents with suggested activity against SARS-CoV2 within 28 days before enrollment(14) Deemed ineligible as determined by the principal investigator or a co-investigator

(1) Performance status of 2 or greater(2) Advanced liver function abnormalities classified as grade C by the Child-Pugh criteria(3) End-stage renal disease requiring dialysis(4) Altered mental status(5) Pregnant or planning pregnancy(6) If female, not agreeable to using oral contraceptive, intrauterine contraceptive device, mechanical contraceptive methods such as pessaries and condoms, or combinations thereof, during favipiravir administration and 90 days thereafter(7) If male, has a female partner who is not agreeable to the contraceptive methods described in (7) (8) If male, not agreeable to using condoms during favipiravir administration and 90 days thereafter(9) History of hereditary xanthine oxidase deficiency(10) History of hypouricemia (less than 1 mg/dL) or xanthine urolithiasis(11) History of uncontrolled gout or hyperuricemia (12) History of immunocompromising conditions such as HIV positivity(13) Has received systemic agents with suggested activity against SARS-CoV2 within 28 days before enrollment(14) Deemed ineligible as determined by the principal investigator or a co-investigator